Novo Nordisk: marketing application to EMA for Ozempic

(CercleFinance.com) - Novo Nordisk announced on Tuesday that it has submitted a marketing application to the European Medicines Agency (EMA) for a new dosage of Ozempic (semaglutide) - in this case 2mg - for the treatment of type 2 diabetes in adults.

Ozempic is currently approved in the EU in doses of 0.5mg and 1mg.

This application is based on the results of the Sustain Forte trial, which show a 'statistically significant' efficacy of the 2mg dose compared to the 1mg dose.

Mads Krogsgaard Thomsen, executive vice president and chief scientific officer of Novo Nordisk, said, "With the 2.0 mg dose, more people with type 2 diabetes will be able to achieve treatment target".


Copyright (c) 2020 CercleFinance.com. All rights reserved.